Share
SAN DIEGO – January 5, 2021 – Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced that Kevin Finney, chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021 at 12:10 p.m. ET.
About Autobahn Therapeutics
Autobahn Therapeutics is focused on restoring hope for people affected by CNS disorders. Autobahn is leveraging its brain-targeting chemistry platform to unlock new therapeutic opportunities through precision tuning of the central exposure of its molecules. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta agonist for the treatment of adrenomyeloneuropathy (AMN), a rare genetic disorder. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com.
Contact:
Alicia Davis, THRUST Strategic Communications
alicia@thrustsc.com